Neurocrine Bio. (NBIX) Survey Favors NBIX Over TEVA, Raising PT - Jefferies

Jefferies analyst Biren Amin, surveyed 50 U.S. doctors on the current and future Tardive Dyskinesia (TD) and Tourette’s Syndrome (TS) treatment landscapes to gauge the outlook for Neurocrine Bio. (NASDAQ: NBIX) valbenazine and TEVA’s deutetrabenazine. Respondents estimated significant uptake of both drugs but were more bullish on valbenazine. The survey also indicates a larger moderate-to-severe TD population which results in a new PT of $61 (prev $58).

SI Note: NBIX was highlighted in the Stealth Growth Insider newsletter on Thursday, 5/18.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $47.89 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Macquarie Upgrades ASM Pacific Technology (522:HK) (ASMVY) to Outperform